News
Chinese regulator grants second approval for lung cancer drug ivonescimab, which has outperformed Merck’s Keytruda in phase ...
2500.HK Venus Medtech (Hangzhou) Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback